Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014; 20(18): 5302-5307
Corresponding Author of This Article
Yesim Ozen Alahdab, MD, Department of Gastroenterology and Hepatology, Fatih Sultan Mehmet Education and Research Hospital, E5 Karayolu Uzeri Icerenkoy-Atasehir, 34752 Istanbul, Turkey. firstname.lastname@example.org
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yesim Ozen Alahdab, Department of Gastroenterology and Hepatology, Fatih Sultan Mehmet Education and Research Hospital, 34752 Istanbul, Turkey
Cem Kalayci, Department of Gastroenterology and Hepatology, Feneryolu Mh Kadikoy, 34724 Istanbul, Turkey
ORCID number: $[AuthorORCIDs]
Author contributions: Alahdab YO and Kalayci C contributed to this paper equally.
Correspondence to: Yesim Ozen Alahdab, MD, Department of Gastroenterology and Hepatology, Fatih Sultan Mehmet Education and Research Hospital, E5 Karayolu Uzeri Icerenkoy-Atasehir, 34752 Istanbul, Turkey. email@example.com
Telephone: +90-532-7230290 Fax: +90-216-5750406
Received: September 30, 2013 Revised: November 25, 2013 Accepted: January 6, 2014 Published online: May 14, 2014
Helicobacter pylori (H. pylori) is a prevalent, worldwide, chronic infection. Choice of treatment can be modified according to antibiotic-resistance rates of H. pylori. The ideal therapeutic regimen for H. pylori infection should achieve an eradication rate of ≥ 80%. In some countries, triple therapy with a proton-pump inhibitor (PPI), clarithromycin, and amoxicillin or metronidazole is still the best option. Bismuth-containing quadruple therapy consisting of bismuth salts, tetracycline, metronidazole and PPI, may be the preferred option in countries with clarithromycin resistance > 20%. Sequential therapy including a PPI and amoxicillin given for the first 5 d, followed by triple therapy including a PPI, clarithromycin, and nitroimidazole antimicrobial (all twice daily) for the remaining 5 d, can be another option for the first-line treatment of H. pylori. Recent data suggest that treatment with PPI, levofloxacin, and amoxicillin for 10 d is a good choice for second-line therapy. Concomitant therapy consisting of PPI, amoxicillin, clarithromycin and metronidazole is another option for second-line treatment. If second-line treatment also fails, it is recommended to culture H. pylori from biopsy specimens and perform antimicrobial susceptibility testing. Rescue treatment should be based on antimicrobial susceptibility.
Core tip:Helicobacter pylori (H. pylori) is a prevalent, worldwide, chronic infection. The ideal therapy regimen for H. pylori infection should achieve an eradication rate ≥ 80%. Triple therapy remains an appropriate first-line therapy in areas of low clarithromycin resistance, and quadruple therapy should be the first-line therapy in areas of high clarithromycin resistance. Sequential therapy can be an alternative. Levofloxacin-containing regimens or concomitant therapies can be good choices for second-line therapy. Choice of treatment regimen for H. pylori infection should be done cautiously and antibiotic-resistance rates should be taken into consideration.
Citation: Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014; 20(18): 5302-5307
The ideal therapeutic regimen for Helicobacter pylori (H. pylori) infection should achieve an eradication rate of ≥ 80%. Treatment may depend on the patient, treatment indication, local antibiotic-resistance profile, and whether the patient was treated previously for H. pylori infection.
Triple therapy, comprising two antibiotics, amoxicillin and clarithromycin, and a proton pump inhibitor (PPI) for 1 or 2 wk (Table 1), was recommended as the initial treatment of choice at several consensus conferences[1,2]. Eradication rates with triple therapy range between 70% and 85%[3-5]. Most studies support that 1 and 2 wk triple therapy is associated with similar eradication rates[6,7]. In contrast, the superiority of 2-wk triple therapy over 1-wk triple therapy has been confirmed by a recent large randomized single center trial from Italy. In an intention-to-treat analysis, 2-wk triple therapy with omeprazole, amoxicillin and clarithromycin achieved a significantly higher eradication rate than 1-wk triple therapy (70% vs 57%, P = 0.05). The most frequently reported side effects include gastrointestinal (GI) upset, diarrhea, and altered taste for clarithromycin, and GI upset, headache, and diarrhea for amoxicillin. However, rates of H. pylori eradication using traditional clarithromycin-containing triple therapies have decreased because of increasing clarithromycin resistance.
PPI (twice daily) + bismuth subsalicylate (525 mg 4 times daily) + metronidazole (250 mg 4 times daily) + tetracycline (500 mg 4 times daily)
PPI (twice daily) + levofloxacin (250 mg twice daily) + amoxicillin (1 g twice daily)
PPI (twice daily) + amoxicillin (1 g twice daily) for the first 5 d, followed by PPI + clarithromycin (500 mg twice daily) + nitroimidazole/tinidazole (500 mg twice daily)
PPI (twice daily) + amoxicillin (1 g twice daily) + clarithromycin (500 mg twice daily) + metronidazole
Levofloxacin-containing sequential therapy
PPI +amoxicillin (1 g twice daily) for the first 5 d followed by PPI + levofloxacin (500 mg daily) + metronidazole (500 mg twice daily)
Triple therapy regimens are becoming less effective, therefore, alternative therapies are needed. Quadruple therapy containing PPI, bismuth, metronidazole and tetracycline given for 10-14 d (Table 1) is a good alternative for first-line treatment of H. pylori infection[2,10]. Success rates range between 75% and 90%. Side effects of metronidazole include a metallic taste in the mouth, dyspepsia, and a disulfiram-like reaction with alcohol consumption. Side effects of tetracycline include GI upset and photosensitivity. Bismuth compounds have been associated with darkening of the tongue and stools, nausea, and GI upset. According to the Maastricht III and Maastricht IV Consensus, bismuth-containing quadruple therapy is recommended as first-line therapy, especially in areas with a high prevalence (> 20%) of clarithromycin resistance[1,10].
In a meta-analysis comprising 51 trials to 2004, it was reported that quadruple therapy cures > 85% of H. pylori infections. These data were supported by another meta-analysis that reported an eradication rate of 82.6% with bismuth-containing quadruple therapy.
The success rate of bismuth-containing quadruple therapy is reported as > 90% from different parts of the world[14-16]. In a meta-analysis comprising four randomized control trials (RCTs), eradication rates with bismuth-containing quadruple therapy vs clarithromycin-containing triple therapy were reported as 81% vs 78% (OR = 0.83; 95%CI: 0.61-1.14; P = 0.3). According to these data, quadruple and triple therapies seem to be equivalent in terms of effectiveness, compliance and side-effect proﬁle when administered as ﬁrst-line treatment for H. pylori infection. Another meta-analysis reported similar eradication rates for quadruple and triple therapies as first-line therapy for H. Pylori infection. They reported a quadruple-therapy eradication rate of 78.3%, whereas the eradication rate of triple therapy was 77.0% (RR = 1.002, 95%CI: 0.936-1.073). A recent meta-analysis showed that eradication rate of quadruple therapy was 77.6%, whereas triple therapy was 68.9% [risk difference (RD) = 0.06, 95%CI: 0.01-0.13]. In the subgroup analysis of treatment duration, the 10-d quadruple therapy achieved eradication rate of 82.5%, whereas triple therapy achieved an eradication rate of 57.7% (RD = 0.25, 95%CI: 0.18-0.32). Thus, 10-d quadruple therapy was shown to be more effective than the 7-d triple therapy. It is suprising that in these reports both therapies yielded overall similar but suboptimal eradication rates, as distinct from the success rate of quadruple therapy trials.
In contrast, there are trials showing that quadruple therapy is better than triple therapy. In a trial consisting of 440 patients, H. pylori eradication rate of quadruple therapy in intention-to-treat analysis was 80%, whereas eradication rate of triple therapy was 55% (P < 0.0001). H. pylori eradication rate of quadruple therapy in per-protocol analysis was 93%, whereas eradication rate of triple therapy was 70% (P < 0.0001). In another study, the intention-to-treat eradication rates in quadruple and triple therapies were reported as 89.4% and 63.5%, respectively (P < 0.05). By per protocol analysis, the eradication rates of the two groups were 91.6% and 65.1%, respectively (P < 0.05).
The sequential regimen is a simple dual therapy including a PPI plus 1 g amoxicillin (both twice daily) given for the first 5 d, followed by triple therapy including a PPI, 500 mg clarithromycin, and a nitroimidazole antimicrobial (all twice daily) for the remaining 5 d (Table 1). Its initial reported success rate was > 90%[22,23]. Initial studies of sequential therapy suggested that its superiority over standard triple therapy might be due to improved eradication of clarithromycin-resistant strains[24,25]. In a recent study comparing sequential and triple therapy, H. pylori eradication rates were 77.8% vs 62.2%, respectively (P = 0.002). In this study, the reported eradication rate of sequential therapy was lower than in previous studies. In a multicenter study from Latin America comprising 1463 patients, sequential therapy was not significantly better than standard triple therapy. Eradication rates were 82.2% vs 76.5% for triple and sequential therapy, respectively. In an other meta-analysis, the overall eradication rate of sequential therapy was reported to 84.3%, and it was not superior to 14-d triple therapy, bismuth-containing quadruple therapy, and non-bismuth quadruple therapy.
It has been suggested that levoﬂoxacin rather than clarithromycin can achieve better eradication rates in sequential regimes. Eradication rates of levofloxacin containing sequential therapy were reported as 95.1% and 90% from Taiwan and Turkey, respectively[29,30].
In patients who were treated for H. pylori infection, and did not achieve eradication, second-line therapy is required. The Maastricht IV consensus states that if triple therapy fails, either a bismuth-containing quadruple therapy or levofloxacin-containing triple therapy can be used as second-line therapy.
Levofloxacin-containing therapy can be used as second-line therapy in case of triple-therapy failure[31-33] or as second-line therapy in case of failure of bismuth-containing quadruple therapy in areas of high clarithromycin resistance. Levofloxacin-containing therapy consists of PPI, levofloxacin and amoxicillin and is used for 10 d (Table 1). Side effects of levofloxacin consist of anorexia, nausea, vomitting and abdominal discomfort. It may also cause mild headache and dizziness.
In two different meta-analyses it has been shown that levofloxacin therapy was superior to quadruple therapy as second-line treatment of H. pylori infection. Meta-analysis also showed that levofloxacin-based triple therapy has fewer adverse effects and is better tolerated than quadruple-therapy regimens. After H. pylori eradication failure, levofloxacin triple therapy is more effective and better tolerated than bismuth-containing quadruple therapy[34,35]. In spite of these results, levofloxacin therapy should be used cautiously because of rising rates of levofloxacin resistance.
Levofloxacin therapy can also be good as an alternative after failure of non-bismuth-containing quadruple sequential or concomitant treatment to eradicate H. pylori infection.
Classical concomitant or non-bismuth-based quadruple therapy consists of PPI, amoxicillin, clarithromycin and metronidazole (Table 1). Eradication rates of 94.9% and 91.4% were obtained with non-bismuth-containing quadruple therapy in studies from Japan and Greece, respectively[37,38]. A meta-analysis comprising 19 studies (2070 patients) revealed a mean H. pylori eradication rate of 88% for non-bismuth- containing quadruple therapy. In this meta-analysis, it has been shown that concomitant therapy was more effective than triple therapy with an eradication rate of 90% vs 78%, respectively.
Rifabutin-based rescue therapy constitutes an encouraging strategy after previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin. Rifabutin can be an alternative to bismuth-based quadruple salvage therapy. In trials using rifabutin-based therapy, eradication rates are reported at > 80%[41,42]. Side effects of rifabutin include rash and GI upset such as nausea, vomiting, dyspepsia and diarrhea, and red discoloration of urine. Rarely, rifabutin is associated with myelotoxicity and ocular toxicity.
If second-line treatment also fails, it is recommended to culture H. pylori from biopsy specimens and perform antimicrobial susceptibility testing[10,44].
PENICILLIN ALLERGIC PATIENTS
PPI, clarithromycin and metronidazole therapy can be first-line treatment for the patients with penicillin allergy living in areas of low clarithromycin resistance. PPI, tetracycline and metronidazole regimens or bismuth-containing quadruple therapy can be used in areas of high clarithromycin resistance. As an alternative treatment PPI, bismuth subcitrate, rifabutin and ciprofloxacin are used for patients with penicillin allergy and this therapy gave an eradication rate of 94.2%.
There is some evidence that adding 500 mg vitamin C plus 200 U vitamin E twice daily for 30 d may increase H. pylori eradication rate[48,49]. Similarly, adding bovine lactoferrin to H. pylori eradication therapy potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings. In a study from Turkey, it has been shown that Saccharomyces boulardii had no significant affect on the rate of H. pylori eradication. In contrast, S. boulardii improved antibiotic-therapy-associated diarrhea, epigastric discomfort, and treatment tolerability[51,52]. However, systemic review of five RCTs evaluating addition of S. boulardii to triple therapy showed that S. boulardii given along with triple therapy significantly increased the eradication rate (4 RCTs, n = 915, RR = 1.13, 95%CI: 1.05-1.21) and reduced the risk of overall H. pylori therapy-related adverse effects, particularly of diarrhea (4 RCTs, n = 1215, RR = 0.47, 95%CI: 0.32-0.69).
There are some factors affecting eradication success. Cytochrome P450 2C19 (CYP2C19) and P-glycoprotein (MDR1) gene polymorphisms, which influence the clearance of PPIs, and thus their effect on gastric acid secretion, may affect the therapeutic efﬁcacy of a PPI-based eradication therapy for H. pylori infection. In particular, T/T genotype of the MDR1 C3435T polymorphism could be a predictive indicator of the lower eradication rate of a PPI-based eradication therapy. The usage of high-dose PPI instead of standard dose can increase the efficacy of treatment. According to a meta-analysis, high-dose PPI is more effective than standard dose, and increases eradication rate by approximately 8%.
Smoking decreases the treatment success rate for H. pylori eradication. In a meta-analysis consisting of 22 published studies, it has been reported that the mean difference in eradication rates between smokers and nonsmokers was 8.4%.
Triple therapy remains an appropriate first-line therapy in areas of low clarithromycin resistance; conversely, quadruple therapy should be the first-line therapy in areas of high clarithromycin resistance. The usage of sequential therapy has become increasingly common, however, more data are needed before recommending sequential therapy as first-line therapy. Levofloxacin-containing regimens or concomitant therapies can be good choices for second-line therapy. Choice of treatment regimen of H. pylori should be done cautiously and resistance rates of antibiotics should be taken into consideration.
P- Reviewers: De Francesco V, Vale FF S- Editor: Zhai HH L- Editor: Kerr C E- Editor: Ma S
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.Gut. 2007;56:772-781.
Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection.Am J Gastroenterol. 2007;102:1808-1825.
Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.Aliment Pharmacol Ther. 2011;34:1255-1268.
Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J, Matsubara Y, Miwa J, Yakabi K. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan.J Gastroenterol. 2012;47:276-283.
Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study.Gastroenterology. 2002;123:1763-1769.
Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.Ann Intern Med. 2007;147:553-562.
Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.Gut. 2007;56:475-479.
Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, Rossi P, Gurnari M, Caracciolo F, Zippi M. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study.Helicobacter. 2006;11:562-568.
Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond.Drugs. 2008;68:725-736.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.Gut. 2012;61:646-664.
Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection.Hosp Pract (1995). 2011;39:133-140.
Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.Aliment Pharmacol Ther. 2004;20:1071-1082.
Buzás GM, Józan J. First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004.World J Gastroenterol. 2006;12:5311-5319.
Ergül B, Doğan Z, Sarikaya M, Filik L. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.Helicobacter. 2013;18:454-458.
Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.Eur J Gastroenterol Hepatol. 2013;25:1134-1140.
Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.Helicobacter. 2011;16:295-300.
Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.Aliment Pharmacol Ther. 2003;17:1137-1143.
Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.Am J Gastroenterol. 2010;105:65-73.
Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.Digestion. 2013;88:33-45.
Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.Lancet. 2011;377:905-913.
Zheng Q, Chen WJ, Lu H, Sun QJ, Xiao SD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance.J Dig Dis. 2010;11:313-318.
Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, Cavina M, Ierardi E, Morini S, Vaira D. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.Aliment Pharmacol Ther. 2005;21:1419-1424.
Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.Can J Gastroenterol. 2006;20:113-117.
Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F. High eradication rates of Helicobacter pylori with a new sequential treatment.Aliment Pharmacol Ther. 2003;17:719-726.
Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial.Ann Intern Med. 2007;146:556-563.
Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.Aliment Pharmacol Ther. 2012;35:56-65.
Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.Lancet. 2011;378:507-514.
Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.BMJ. 2013;347:f4587.
Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.J Antimicrob Chemother. 2011;66:1847-1852.
Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.Eur J Intern Med. 2012;23:165-168.
Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.J Clin Gastroenterol. 2013;47:130-135.
Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.J Antimicrob Chemother. 2009;63:1017-1024.
Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sánchez-Pobre P. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.Am J Gastroenterol. 2008;103:71-76.
Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.Aliment Pharmacol Ther. 2006;23:35-44.
Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.Am J Gastroenterol. 2006;101:488-496.
Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection.Scand J Gastroenterol. 2013;48:652-656.
Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.World J Gastrointest Pharmacol Ther. 2012;3:1-6.
Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing “concomitant” therapy as first-line Helicobacter pylori eradication regimen in Greece.Helicobacter. 2012;17:49-53.
Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.Clin Exp Gastroenterol. 2012;5:23-34.
Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bästlein E, Jacobs E, Bayerdörffer E. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.Aliment Pharmacol Ther. 2006;24:395-403.
Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.Am J Gastroenterol. 2001;96:58-62.
Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.J Clin Gastroenterol. 2000;31:222-225.
Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, Llorente R, Ng C. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection.Aliment Pharmacol Ther. 2006;23:481-488.
Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection.Aliment Pharmacol Ther. 2004;19:789-795.
Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin.Aliment Pharmacol Ther. 2005;22:1041-1046.
Rodríguez-Torres M, Salgado-Mercado R, Ríos-Bedoya CF, Aponte-Rivera E, Marxuach-Cuétara AM, Rodríguez-Orengo JF, Fernández-Carbia A. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.Dig Dis Sci. 2005;50:634-639.
Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.Aliment Pharmacol Ther. 2012;36:1076-1083.
Sezikli M, Çetinkaya ZA, Güzelbulut F, Yeşil A, Coşgun S, Kurdaş OÖ. Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori.J Clin Pharm Ther. 2012;37:282-285.
Sezikli M, Cetinkaya ZA, Sezikli H, Güzelbulut F, Tiftikçi A, Ince AT, Gökden Y, Yaşar B, Atalay S, Kurdaş OO. Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate?Helicobacter. 2009;14:280-285.
Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication.Aliment Pharmacol Ther. 2009;29:720-730.
Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.Helicobacter. 2007;12:309-316.
Duman DG, Bor S, Ozütemiz O, Sahin T, Oğuz D, Iştan F, Vural T, Sandkci M, Işksal F, Simşek I. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication.Eur J Gastroenterol Hepatol. 2005;17:1357-1361.
Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment.Aliment Pharmacol Ther. 2010;32:1069-1079.
Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.Eur J Clin Pharmacol. 2005;61:375-379.
Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.Aliment Pharmacol Ther. 2007;26:693-703.
Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.Aliment Pharmacol Ther. 2008;28:868-877.
Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R. Smoking increases the treatment failure for Helicobacter pylori eradication.Am J Med. 2006;119:217-224.